Y. Kato et al., SHORT-TERM TREATMENT WITH DIFFERENT DOSES OF HUMAN GROWTH-HORMONE IN ADULT PATIENTS WITH GROWTH-HORMONE DEFICIENCY, Endocrine journal, 43(2), 1996, pp. 177-183
We studied the effects of short term replacement with human GH at thre
e doses (0.124, 0.250 and 0.375 IU/kgBW/week) in 12 adult patients wit
h GH deficiency (GHD). The patients were divided at random into three
goups of 4 patients (groups A, B and C) and each group was treated wit
h three doses of GH and placebo for 10 weeks in shifts of two weeks ea
ch. The replacement was started with one of three doses of GH given sc
daily at 2100 h for 2 weeks, which was followed by placebo treatment
for 2 weeks. The various doses of GH and placebo were then given alter
nately. GH treatment increased serum IGF-I and IGF-BPS levels in all t
he patients examined although the responses were partly influenced by
the order of GH treatment. When the data obtained with the same doses
of GH in the three groups were combined, a dose-response was demonstra
ted. There was a close correlation (r=0.726) between serum IGF-I and I
GFBP-3. Serum triiodothyronine as well as non-esterified fatty acid (N
EFA) levels also increased after GH replacement. Adverse side effects
included edema in two cases and sleep distress in one case during the
GH treatment at the highest dose of 0.375 IU/kgBW/week. These findings
indicate that short term replacement with GH at the doses of 0.125 an
d 0.250 IU/kgBW/week is safe and effective in adult patients with GHD.